Pernix Therapeutics to Report Third Quarter 2016 Financial Results on November 10, 2016
31 oct. 2016 16h30 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today...
Pernix Therapeutics Announces Reverse Stock Split and Corporate Governance Enhancements
13 oct. 2016 08h56 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced...
Pernix Therapeutics Announces Distribution of TREXIMET® 10/60 mg (sumatriptan 10mg and naproxen sodium 60 mg) Dose For Use in Pediatric Patients
28 sept. 2016 16h01 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced...
Marsha Stanton, Ph.D., RN, Pernix Therapeutics Executive Director of Medical and Government Affairs, Awarded Prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing®
16 sept. 2016 07h00 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced...
Pernix Therapeutics Announces the Issuance of Two New Orange Book Listed Patents for Zohydro® ER with BeadTek™
14 sept. 2016 07h00 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the United States Patent and...
Pernix Therapeutics Announces Significant Presence at PAINWeek 2016
09 sept. 2016 08h00 HE
|
Pernix Therapeutics Holdings, Inc.
Company’s Poster Presentation Highlighted Results of Study Evaluating Hepatic or Renal Impairment on the Pharmacokinetics of Zohydro® ERPernix Also Sponsored a Well-Attended Symposium Focused on...
Pernix Therapeutics Reports Second Quarter 2016 Financial Results and Business Update
11 août 2016 16h01 HE
|
Pernix Therapeutics Holdings, Inc.
Net Revenue Increased 13% Sequentially Over First Quarter 2016 Recently Completed Reorganization of Management Team and Restructuring of Sales Force and Operations MORRISTOWN, N.J., Aug. 11, 2016...
Pernix Therapeutics to Report Second Quarter 2016 Financial Results on August 11, 2016
04 août 2016 06h30 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial...
Pernix Therapeutics Announces Reorganization of Senior Management Team
26 juil. 2016 17h40 HE
|
Pernix Therapeutics Holdings, Inc.
John Sedor Appointed CEO on a Permanent Basis Company Names Pharmaceutical Industry Veteran, Dr. Graham Miao, as President & CFO Company Positioned to Maximize Value and Drive Revenue Growth...
Pernix Therapeutics Announces Restructuring of Sales Force and Operations
07 juil. 2016 06h30 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J. , July 07, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced an initiative...